The association of body mass index and prostate-specific antigen in a population-based study

Jacques Baillargeon; Brad H. Pollock; Alan R. Kristal; Patrick Bradshaw; Javier Hernandez; Joseph Basler; Betsy Higgins; Steve Lynch; Thomas Rozanski; Dean Troyer; Ian Thompson

doi:10.1002/cncr.20856

The association of body mass index and prostate-specific antigen in a population-based study

Jacques Baillargeon, Brad H. Pollock, Alan R. Kristal, Patrick Bradshaw, Javier Hernandez, Joseph Basler, Betsy Higgins, Steve Lynch, Thomas Rozanski, Dean Troyer, Ian Thompson

Research output: Contribution to journal › Article › peer-review

199 Scopus citations

Abstract

BACKGROUND. Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma. METHODS. The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute. RESULTS. The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age. CONCLUSIONS. Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.

Original language	English (US)
Pages (from-to)	1092-1095
Number of pages	4
Journal	Cancer
Volume	103
Issue number	5
DOIs	https://doi.org/10.1002/cncr.20856
State	Published - Mar 1 2005

Keywords

Body mass index
Cancer risk
Prostate carcinoma
Prostate-specific antigen

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.20856

Fingerprint Dive into the research topics of 'The association of body mass index and prostate-specific antigen in a population-based study'. Together they form a unique fingerprint.

Cite this

The association of body mass index and prostate-specific antigen in a population-based study. / Baillargeon, Jacques; Pollock, Brad H.; Kristal, Alan R.; Bradshaw, Patrick; Hernandez, Javier; Basler, Joseph; Higgins, Betsy; Lynch, Steve; Rozanski, Thomas; Troyer, Dean; Thompson, Ian.

In: Cancer, Vol. 103, No. 5, 01.03.2005, p. 1092-1095.

Research output: Contribution to journal › Article › peer-review

@article{0517262e547c4a519d4cfc05be46533c,

title = "The association of body mass index and prostate-specific antigen in a population-based study",

abstract = "BACKGROUND. Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma. METHODS. The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute. RESULTS. The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age. CONCLUSIONS. Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.",

keywords = "Body mass index, Cancer risk, Prostate carcinoma, Prostate-specific antigen",

author = "Jacques Baillargeon and Pollock, {Brad H.} and Kristal, {Alan R.} and Patrick Bradshaw and Javier Hernandez and Joseph Basler and Betsy Higgins and Steve Lynch and Thomas Rozanski and Dean Troyer and Ian Thompson",

year = "2005",

month = mar,

day = "1",

doi = "10.1002/cncr.20856",

language = "English (US)",

volume = "103",

pages = "1092--1095",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - The association of body mass index and prostate-specific antigen in a population-based study

AU - Baillargeon, Jacques

AU - Pollock, Brad H.

AU - Kristal, Alan R.

AU - Bradshaw, Patrick

AU - Hernandez, Javier

AU - Basler, Joseph

AU - Higgins, Betsy

AU - Lynch, Steve

AU - Rozanski, Thomas

AU - Troyer, Dean

AU - Thompson, Ian

PY - 2005/3/1

Y1 - 2005/3/1

N2 - BACKGROUND. Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma. METHODS. The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute. RESULTS. The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age. CONCLUSIONS. Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.

AB - BACKGROUND. Recent studies of men with prostate carcinoma suggest that obesity may be associated with more advanced-stage disease and lower overall survival rates. One possible link between body mass index (BMI) and prostate carcinoma prognosis may be disease ascertainment. Prostate-specific antigen (PSA) is widely used to screen for prostate carcinoma. METHODS. The authors examined the association between BMI and PSA in a population-based study of 2779 men without prostate carcinoma. Between 2001 and 2004, these men were enrolled in a study sponsored by the San Antonio Center of Biomarkers of Risk, a clinical and epidemiologic center of the Early Detection Research Network of the National Cancer Institute. RESULTS. The mean PSA value decreased in a linear fashion with an increase in BMI category, from 1.01 ng/mL in normal weight men to 0.69 ng/mL in obese (Class III) men, after adjusting for race/ethnicity and age. CONCLUSIONS. Lower levels of PSA in obese and overweight men could mask biologically consequential prostate carcinoma.

KW - Body mass index

KW - Cancer risk

KW - Prostate carcinoma

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=13944272257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944272257&partnerID=8YFLogxK

U2 - 10.1002/cncr.20856

DO - 10.1002/cncr.20856

M3 - Article

C2 - 15668913

AN - SCOPUS:13944272257

VL - 103

SP - 1092

EP - 1095

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -

The association of body mass index and prostate-specific antigen in a population-based study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this